OptimizeRx Corporation Third Quarter 2026 Conference Call - OPTIMIZERX CORP

Financial Performance:

• Q3 FY2026 revenue was $21.6 million (down 17% YoY), missing full-year guidance but exceeding consensus expectations due to strong profitability.
• Adjusted EBITDA was $6.3 million (up from $5.1 million YoY), representing an impressive margin of approximately 29% compared to 20% in the prior year.
• Net income was $1.2 million ($0.06/share) GAAP basis, and $3.8 million ($0.20/share) on a non-GAAP basis.
• Gross margins remain strong in the low 70% range for full year 2026, driven by a favorable product mix and reduction in low-margin managed services.
• Operating expenses decreased by $5.1 million YoY to $18.9 million, aided by cost-cutting initiatives, though impacted by $0.7 million in severance costs.
• Operating cash flow for the first three quarters was $12.9 million; cash balance stood at $22.3 million at quarter-end.
• Debt reduction accelerated: $6.3 million in principal paid in Q3 ($6M ahead of schedule), with an additional $3 million paid post-quarter, reducing outstanding debt to $10.4 million.
• Net Revenue Retention (NRR) dipped to 83%, driven by a significant reduction in spending from one large displaced client who represented ~10% of revenue in the prior year.
• Revenue per FTE was $706,000.

Guidance and Future Outlook:

• Updated full-year FY2026 revenue guidance to $87 million–$93 million (down from previous projections), citing contracted revenue tracking ~20% below prior year levels and delays in customer budget decisions.
• Maintained full-year adjusted EBITDA guidance at $21 million–$25 million.
• Full-year revenue target implies Q4 revenue will be lower YoY, with management estimating only ~90% of the full-year revenue is currently contracted compared to mid-90% in previous years.
• FY2027 outlook is positive: contracted revenue for 2027 is tracking approximately 20% ahead year-over-year, with management anticipating growth rates similar to 2025 levels.
• Management expects NRR to normalize and improve in 2027 following the recovery of spending from the displaced major client.
• Long-term goals include achieving 30%+ EBITDA margins as the business scales and growing recurring revenue opportunities.
• Management anticipates increased share repurchase activity in Q4 2026.

Business Segments and Product Lines:

• Displaced top-5 client returned in Q4, beginning reinvestment in new solutions, though spending has not yet returned to historical levels.
• Programmatic distribution strategy expanded with integrations with three major Demand-Side Platforms (DSPs): DeepIntent, The Trade Desk, and PulsePoint.
• PulsePoint partnership is expected to contribute ~250,000 incremental NPIs (New Patient Impressions) to the network by November.
• Trade Desk integration via Open Path now provides access to over 800,000 verified healthcare professionals across 400+ EHR systems.
• Enhanced Natural Language Audience Builder (NLAB) extended to include privacy-safe Direct-to-Consumer (DTC) audiences, enabling coordinated HCP and consumer targeting.
• Mid-tier and long-tail clients are showing "exceptionally good play," with one mid-tier client joining the top 10 client pool in recent quarters.
• New customer wins include mid-tier pharma, biotech, and medtech companies.
• Strategic hires include Sarah Bass as Chief Marketing Officer to strengthen go-to-market strategy and agency relationships.

Market and Competitive Landscape:

• Pharmaceutical marketing environment remains dynamic with budget scrutiny, MFN pricing uncertainty, and delays in campaign execution.
• OptimizeRx differentiates itself as the only tech company with an AI-enabled operating system and a proprietary network of 450+ EHR/e-prescribing systems reaching 1.1M+ verified HCPs.
• The company is shifting from a direct sales model to a scalable programmatic distribution infrastructure.
• Competitors with subscription-based models are seeing growth, serving as a bellwether for industry trends.
• Market sentiment indicates pent-up demand as customers evaluate remaining marketing budgets and the "use-it-or-lose-it" nature of Q1-Q4 warehoused dollars.

Risks and Challenges:

• Primary revenue risk is the timing of customer spending conversion; contracted revenue is 20% below prior year, increasing reliance on Q4 buy-ups.
• Dependency on a concentrated group of top 20 customers remains a risk, evidenced by the recent NRR dip.
• Regulatory uncertainty regarding drug pricing (e.g., MFN) and political shifts (election outcomes) causing client hesitation.
• Execution risk in converting 2027 RFP momentum into recognized 2026 revenue.
• Potential future losses from contracts expiring (LOE) in 2028, though no major divots expected in 2027.

Management Commentary and Tone:

• Tone is confident regarding long-term technology advantages and 2027 growth potential but cautious on near-term 2026 revenue recognition.
• Management emphasizes structural improvements, margin expansion, and cost discipline as core strengths.
• CEO Steven Silvestro thanked outgoing CFO Edward Stelmach for his five-year tenure; Stelmach will serve as a strategic advisor through year-end.
• Andy DeSilva will become CFO and Heather Favaza Chief Accounting Officer effective January 1, 2027.
• Management highlighted the best "mojo" and culture in a long time, driven by new commercial hires and product innovation.

Analyst Questions and Answers:

• Programmatic Runway: Management confirmed the three DSP partners (DeepIntent, Trade Desk, PulsePoint) represent 60-70% of the volume in the programmatic space, viewing the current stage as "early innings."
• Mid/Long-Tail Growth: Strong demand from mid-tier and long-tail clients is offsetting top-tier weakness; growth in this segment is in the double digits.
• NRR Trajectory: Management views the 83% NRR as a temporary disruption due to one client; expects significant improvement in 2027.
• 2027 Guidance: No specific floor or guidance provided yet, but contracted revenue is up 20% YoY, suggesting growth rates closer to 2025.
• EBITDA Margins: Potential to revisit and exceed 30% EBITDA margins as revenue scales; current 29% quarter demonstrates operating leverage.
• Debt vs. Buybacks: Shift in strategy to accelerate share buybacks in Q4 following accelerated debt repayment.
• Q4 Visibility: 90% of FY26 guidance is contracted; remaining gap relies on Q4 buy-ups which are uncertain but encouraged by pent-up demand signals.
• Regulatory Impact: Clients are uncertain due to potential political shifts, but many have recalibrated budgets assuming lower windfalls than anticipated.

Other Key Points:

• The company is evolving from a point-of-care marketing business to a broader technology platform supporting audience intelligence, media planning, and programmatic activation.
• AI capabilities (DAP, NLAB) and proprietary data are cited as key barriers to entry and sources of competitive advantage.
• Management is committed to maintaining financial discipline while investing in commercial expansion and product innovation.
• The return of the displaced major client in Q4 is a critical catalyst for 2027 growth momentum.